Showing results (471-480 of 545) with videos related to
Sort By:
Pageof 55
The American Journal of Medicine|January 22, 2025
The Safety Profile of Amiodarone Among Older Adults (Age ≥75 Years): A Pharmacovigilance Study from the FDA DataTsahi T Lerman, Chen Gadot, Noam Greenberg, et al.The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 15, 2026
Benefits of Oral Nitrite Supplementation on Mitochondrial Respiration and Physical Function In Older AdultsDaniel E Forman, Subashan Perera, Sruti Shiva, et al.The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 11, 2023
Validation of the Pittsburgh Performance Fatigability Index in the Study of Muscle, Mobility and AgingYujia Susanna Qiao, Jaroslaw Harezlak, Peggy M Cawthon, et al.Circulation|May 28, 2024
Skeletal Muscle SIRT3 Deficiency Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Heart Failure With Preserved Ejection FractionJia-Rong Jheng, Yang Bai, Kentaro Noda, et al.Geroscience|November 21, 2023
Lower muscle mitochondrial energetics is associated with greater phenotypic frailty in older women and men: the Study of Muscle, Mobility and AgingTheresa Mau, Haley N Barnes, Terri L Blackwell, et al.Aging Cell|October 16, 2023
Associations between skeletal muscle energetics and accelerometry-based performance fatigability: Study of Muscle, Mobility and AgingYujia Susanna Qiao, Adam J Santanasto, Paul M Coen, et al.Archives of Internal Medicine|July 11, 2012
Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practiceAmit P Amin, John A Spertus, David J Cohen, et al.JACC. Cardiovascular Interventions|February 5, 2010
Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)Martin B Leon, David E Kandzari, Eric L Eisenstein, et al.Journal of the American College of Cardiology|March 20, 2015
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial InfarctionRobert W Yeh, Dean J Kereiakes, Philippe Gabriel Steg, et al.Heart (British Cardiac Society)|August 6, 2018
Five-year outcomes of transcatheter reduction of significant mitral regurgitation in high-surgical-risk patientsSaibal Kar, Ted Feldman, Atif Qasim, et al.Pageof 55